Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
This study, called ACTOv, is for women who have high-grade serous or endometrioid ovarian cancer that has returned after previous treatment and responded well to platinum-based chemotherapy before. It aims to find out if giving a chemotherapy drug called carboplatin in a more personalised way can be more effective and cause fewer side effects. Instead of a fixed dose every three weeks, the new approach, called "adaptive therapy," adjusts the dose based on changes in a blood test called CA125, which can show how much cancer is present, and how well you responded to previous treatments. Researchers hope this adaptive method could make the carboplatin work for longer, keep the cancer under control for longer, and reduce the overall amount of chemotherapy needed, leading to fewer side effects. Carboplatin is a well-established and generally well-tolerated chemotherapy drug for ovarian cancer.
A colpo d'occhio
Di cosa tratta questo studio?
When ovarian cancer comes back after initial treatment, doctors often use chemotherapy again. One of the main drugs for this is called carboplatin. This study, called ACTOv, is looking at a new, more tailored way to give carboplatin to women whose high-grade serous or endometrioid ovarian cancer has returned.
Currently, carboplatin is usually given at a set dose every three weeks. However, this study wants to try an "adaptive" approach. This means the dose of carboplatin might change over time based on specific information from your body. Doctors will look at your CA125 blood test results (a marker often used to monitor ovarian cancer) and how your body has reacted to past chemotherapy. The idea is that by adjusting the dose, the treatment might be more effective for longer and potentially cause fewer side effects.
The main goal is to see if this adaptive way of giving carboplatin can keep the cancer under control for a longer period and be easier to tolerate than the standard approach. Carboplatin is already a key drug in treating ovarian cancer, known for being relatively affordable and having manageable side effects. This study hopes to make it even better for patients.
Punti chiave
- This study is testing a new way to give carboplatin chemotherapy for relapsed ovarian cancer.
- It focuses on specific types of ovarian cancer (high-grade serous or endometrioid) that have responded to platinum-based chemotherapy before.
- The new method, 'adaptive therapy,' aims to adjust chemotherapy doses based on blood tests (CA125) to improve results and reduce side effects.
- Participation involves regular hospital visits, blood tests, and scans.
- You can stop participating in the study at any time.
- The study hopes to make existing treatments even better for patients.
Chi può essere idoneo?
This study is for women who are at least 18 years old and have been diagnosed with a specific type of ovarian cancer that has come back. This includes high-grade serous or high-grade endometrioid cancer of the ovary, fallopian tube, or peritoneum. You would need to have shown a good response to your most recent chemotherapy treatment, which must have included a platinum drug like carboplatin. You also must have previously received a type of drug called a PARP inhibitor.
Your cancer relapse needs to have been confirmed by a scan at least six months after your last platinum-based chemotherapy. You'll also need to have good general health, including healthy blood, liver, and kidney function. If you could become pregnant, you would need to use effective contraception during the study.
However, you wouldn't be able to join if you have certain other types of ovarian cancer, if you need combination chemotherapy (this study uses carboplatin only), or if you are allergic to carboplatin. You also can't have serious side effects still lingering from previous treatments, except for hair loss or nerve problems.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- Sei una donna di età pari o superiore a 18 anni?
- Do you have high-grade serous or high-grade endometrioid ovarian, fallopian tube, or peritoneal cancer that has returned?
- Did your most recent chemotherapy treatment (which included a platinum drug) help to control your cancer?
- Have you previously received a PARP inhibitor drug?
- Is your general health good enough for new treatment (good blood, liver, and kidney function)?
- Are you willing and able to attend regular appointments and tests?
Cosa comporta la partecipazione?
If you decide to take part in this study, you would be randomly assigned to receive either the standard carboplatin treatment or the new adaptive carboplatin treatment. Both treatments involve receiving carboplatin every three weeks. For the adaptive treatment, your dose might change based on blood test results (CA125) and how you've responded to chemotherapy.
Before starting, you'll have various tests, including scans (CT or MRI) and blood tests, to confirm you meet the study requirements. During the study, you'll have regular blood tests, including CA125, before each carboplatin treatment. Your health will be closely monitored, and you'll have follow-up visits after your treatment finishes, initially every 6 weeks, then every 12 weeks. The total length of your participation would depend on how your treatment progresses and the follow-up schedule.
Rischi e benefici potenziali
Luoghi (1)
- University College London HospitalsCodice postale verificatoLondra, Regno Unito· Reclutamento
Domande comuni
What is carboplatin?
Carboplatin is a common chemotherapy drug used to treat various cancers, including ovarian cancer. It works by slowing down or stopping the growth of cancer cells.
What's the difference between standard and adaptive therapy?
Standard therapy gives a fixed dose of chemotherapy at regular intervals. Adaptive therapy adjusts the dose based on how your body is responding, using markers like the CA125 blood test.
What is CA125?
CA125 is a protein found in the blood. For some women with ovarian cancer, levels of CA125 can be used as a marker to help doctors monitor the disease or how well treatment is working.
Sapró a quale gruppo di trattamento appartengo?
This study uses random assignment, meaning you will be put into one of the treatment groups by chance, like flipping a coin. You might not know which group you are in, but the study team will have this information.
What if my cancer is not high-grade serous or endometrioid?
This study is specifically for high-grade serous or high-grade endometrioid ovarian cancer that has returned. Other types of ovarian cancer are not included in this study.
Come saperne di più
ACTOv Trial Coordinator
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Interessato a partecipare?
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.